

1 **Title:** Real-world evidence: telemedicine for complicated cases of urinary tract infection

2

3 **Running Title:** RWE for telemedicine and complicated UTI

4

5 **Authors:**

6 Natalie M. Daumeyer¹, Daniel Kreitzberg¹, Kathleen M. Gavin^{1,2}, Timothy A. Bauer^{1,2,*}

7

8 ¹Everly Health, Inc., Austin, TX, USA

9 ²University of Colorado Anschutz Medical Campus, Aurora, CO, USA

10

11 *Corresponding author

12 Email: tbauer@everlyhealth.com

13

14 References: 40

15 Tables: 4

16 Figures: 2

17 Appendices: 1

18 Article text: 3,366 words, not including title page, abstract, references, tables, figures, or
19 appendices

20 Abstract: 265 words

21 Key words: antibiotic compliance; cystitis; telehealth; telemedicine; urinary tract infections

22

23 Abbreviations:

24 STIs, sexually transmitted infections; UTIs, urinary tract infections

25

26

27 **Abstract**

28 **Background:** Telemedicine programs for the treatment of urinary tract infections (UTIs) offer an

29 opportunity to reduce burdens on patients and providers. However, these programs are typically

30 restricted to patients with uncomplicated UTIs. This real-world analysis evaluated treatment and
31 resolution rates in a large-scale, national UTI telemedicine program inclusive of patients with
32 uncomplicated and complicated UTIs.

33 **Methods and findings:** We conducted a retrospective analysis of data obtained from a
34 commercially available telemedicine program for the treatment of UTIs among adult women in
35 the US between 2017 and 2021 (n=51,474). The primary outcomes were the number of women
36 who presented with symptoms of uncomplicated UTI, complicated UTI, and vaginal infection;
37 prescription use and antibiotic type; symptom resolution within 7 days after appointment; and
38 treatment failure or relapse. Most patients reported frequent urination (94.4%), urgency (94.5%),
39 and dysuria (97.6%). Those with uncomplicated UTI symptoms represented the majority of
40 patients (61.6%); however, a substantial number of patients (36.5%) also reported at least 1
41 symptom associated with a complicated UTI. One-fifth of patients (19.2%) reported at least 1 co-
42 occurring symptom of vaginal infection or sexually transmitted infection. Across all treated
43 patients, 94.0% received recommended antibiotics according to the clinical protocol. Of the
44 treated patients who provided follow-up data (n=3,521), 89.7% reported 7-day symptom
45 resolution. Symptom resolution rates were similar between patients with uncomplicated UTI
46 symptoms (90.8%) and complicated UTI symptoms (87.9%), and symptom resolution among all
47 treated patients (89.7%) was similar to reports for in-person standard of care.

48 **Conclusions:** These findings suggest that large-scale telemedicine programs for the treatment of
49 UTIs can be effective in the treatment of complicated UTIs.

50

51 **Introduction**

52 Urinary tract infections (UTIs) are some of the most common infections, accounting for millions
53 of visits to healthcare facilities every year [1]. The use of urinalysis in emergency departments to
54 diagnose suspected UTIs has increased from 23% in 2007 to 27% in 2016 [2]. During these
55 visits, patients can spend more than 2 hours waiting for and receiving care, creating a burden for
56 patients [3]. Using telemedicine as an alternative model of care for patients with UTIs would
57 reduce the amount of time patients spend seeking treatment, while freeing up important resources
58 in often over-burdened urgent care and emergency departments, as well as primary care clinics
59 [4,5]. UTIs make up 0.7% of outpatient services, according to projections from US registries [1].
60 Between 1996 and 2001, an average of 7 million women visited healthcare centers in the US for
61 uncomplicated UTIs [6]. There were 10.5 million ambulatory visits for UTIs in the US in 2007
62 (accounting for approximately 1% of all ambulatory visits), of which, 21.3% were to emergency
63 departments [7]. Consultations for UTIs represent between 1% and 6% of all medical visits
64 (~7 million visits and ~\$1.6 billion annually) [8]. Previous research has shown that
65 telemedicine treatment programs are effective for women presenting with uncomplicated UTI
66 symptoms [9-15]. These programs, which largely rely on the application of inclusion/exclusion
67 criteria according to self-reported symptoms and empirical use of antibiotics [16], are similar to
68 in-person care and reduce time to recovery compared with diagnosis using urinalysis [16,17].
69 However, a limitation of these programs is the exclusion of patients who self-reported symptoms
70 of complicated UTIs (e.g., fever, nausea) or vaginal infections (e.g., vaginal discharge, vaginal
71 irritation) [9,11-14]. Thus, it is unclear how effective or safe telemedicine programs can be for
72 patients with these clinical profiles.

73 Women with symptoms of complicated UTIs (e.g., pyelonephritis) are usually referred to
74 in-person care to receive intravenous antibiotics and/or undergo urinalysis to determine the
75 appropriate antibiotic regimen [18,19]. However, some complicated UTI cases can be managed
76 at home without admittance to an emergency department. Researchers have thus begun to
77 question whether higher-risk patients, such as those who report symptoms of pyelonephritis or
78 more complicated UTI, can be treated via telemedicine [15,18,20].

79 In a similar manner, women with vaginal symptoms are often referred to in-person care
80 to rule out other diagnoses, such as sexually transmitted infections (STIs) and vaginal infections
81 [16,21,22]. However, even cases of suspected STI may be managed by remote sample collection
82 and telemedicine services [23]. Recent evidence has shown that vaginal discharge does not
83 reduce the likelihood of a UTI [24], contradicting earlier studies advocating for in-person
84 treatment for women with vaginal symptoms [16]. Thus, with proper symptom screening, which
85 can be implemented virtually, a process for ruling in or out vaginal infections and STIs may be
86 accomplished [25]. Patients with symptoms of complicated UTI or vaginal infection may benefit
87 from a telemedicine approach to care, but current studies evaluating the value of telemedicine
88 have excluded these patients. It remains unknown whether telemedicine provides an alternative,
89 effective pathway to care without compromising on quality.

90 This study examined real-world data from a large telemedicine program that sought to
91 provide treatment for women with UTI symptoms. This UTI telemedicine program is different
92 from previously evaluated programs [15] in the following ways: 1) symptoms reported during
93 the initial screening are included, 2) patients who reported symptoms of complicated UTI and
94 vaginal infection were included, and 3) physicians were given discretion as to whether and how
95 to treat women who reported symptoms of complicated UTI or vaginal infection. The primary

96 outcome measures were the number of women who presented with symptoms of uncomplicated
97 UTI, complicated UTI, and vaginal infection; prescription use and antibiotic type; symptom
98 resolution within 7 days after appointment; and treatment failure or relapse.

99

100 **Methods**

101 *Ethics*


102 This study is a retrospective analysis of real-world data from a nationwide commercial
103 telemedicine program for the treatment of UTIs. The project was deemed exempt from IRB
104 review by WCG Institutional Review Board (IRB00000533) because it does not meet the
105 definition of human subjects research as defined in federal regulation 45 CFR 46.102.

106

107 *Study population and data collection*

108 Individuals in the US seeking care for UTI symptoms between November 2017 and November
109 2021 completed a digital screening process to determine their eligibility for telemedicine
110 services. Patients were excluded for the following reasons: younger than 18 years of age, male,
111 pregnant or breastfeeding, immunocompromising conditions (e.g., HIV, lupus), history of kidney
112 condition, history of urinary condition, history of urologic procedure, history of resistant
113 organisms, or inpatient stay at a healthcare facility within the past 3 months. For this protocol,
114 prior to the COVID-19 pandemic, women aged 65 years or older were excluded if they were
115 currently taking more than 5 prescription medications; this contraindication was removed during
116 the pandemic because of restricted access to in-person care. Cancelled/missed appointments,
117 duplicate records, and follow-up appointments occurring within 30 days after the initial
118 appointment were excluded from the analysis set. Those meeting the criteria reported their

119 symptoms through the digital screener and scheduled a telemedicine consultation. Patients who
120 reported symptoms of a complicated UTI or vaginal infection were able to schedule a
121 telemedicine consultation. Immediately following their consultation, patients received a
122 satisfaction questionnaire. After 7 days, patients received a follow-up questionnaire to assess
123 their symptom resolution. All patients who reported unresolved symptoms received follow-up
124 telemedicine services. Fig 1 shows the participant selection process for this cohort study.
125



126

127

Fig 1. Study flow chart

128

129 *Physician information and the clinical protocol*

130 The median number of consultations was 79 (IQR=623) among 84 physicians. Physician
131 specialties varied and included 51.2% (n=43) family medicine, 29.8% (n=25) internal medicine,
132 11.9% (n=10) emergency medicine, and 4.8% (n=4) preventative medicine, as well as 1
133 physician who was trained in both internal and emergency medicine and 1 physician who was
134 trained as a radiologist. A clinical protocol provided guidance for physicians to diagnose and
135 treat uncomplicated UTIs using the telemedicine platform. The protocol outlined

136 contraindications, considerations for treatment, and recommended antibiotic regimens (see S1
137 Appendix) [18,22,26]. All physicians were trained on the protocol, which was available for
138 reference during consultations. The protocol recommended that patients with symptoms of
139 complicated UTIs or vaginal infection be referred to in-person care. However, physicians were
140 permitted to use their discretion to treat via telemedicine or refer to in-person care. STIs were
141 ruled out during physician consultation based on answers provided on the questionnaire. If
142 providers were unsure about treating a patient, they could escalate the issue to the telemedicine
143 program directors for additional guidance.

144

145 *Measures*

146 *Demographic characteristics.* Patients were asked their age (in years) and sex during the
147 digital screening process before the UTI consultation. The first 3 digits of each patient's zip code
148 were used to determine geographic location.

149 *Symptom presentation groups.* Patients reported the presence of the following 4
150 uncomplicated UTI symptoms: urinary frequency, urinary urgency, dysuria (pain or burning
151 while urinating), and hematuria (blood in the urine). Patients reported the presence of the
152 following complicated UTI symptoms: an oral temperature greater than 99.5 °F; new onset of
153 nausea and/or vomiting; new onset of feelings of general achiness/feeling unwell; back,
154 abdominal, side, or groin pain; international travel within the past 6 months; and dehydration
155 within the past 2 to 3 weeks [5,27,28]. Patients identified the presence of any vaginal infection
156 symptoms: green, yellow, clear, or white discharge; odor from urine/discharge; and vaginal
157 itching, blisters, lesions, or rash. Patients were grouped into 3 categories according to their
158 reported symptom presentation: uncomplicated UTI symptoms, complicated UTI symptoms, and

159 other (see Table 1). Appointments for recurrent infection (i.e., at least 2 appointments in 6
 160 months, aside from relapse, or at least 3 appointments in 12 months, aside from relapse) were
 161 considered a complicated UTI, as long as the patient reported UTI symptoms (even if the patient
 162 had reported only symptoms of uncomplicated UTI during their recurrent visits) [19]. The
 163 presence or absence of vaginal symptoms was also assessed.

164

165 **Table 1. Symptom groups and descriptions.**

Symptom Group	Description	N (%) (N=51,474)
Uncomplicated UTI ^{1,3}	<ul style="list-style-type: none"> ● Patients reporting ≥ 2 of the 4 UTI symptoms, with or without symptoms of vaginal infection ● Not a recurrent infection (first infection in 6 months, or < 3 infections in 12 months) 	31,730 (61.6)
Complicated UTI ^{2,3}	<ul style="list-style-type: none"> ● Patients who reported ≥ 1 of the 4 UTI symptoms AND ≥ 1 symptom of complicated infection, with or without symptoms of vaginal infection (regardless of recurrent infection) <p style="text-align: center;">OR</p> <ul style="list-style-type: none"> ● Any patient with recurrent infection (≥ 2 infections in 6 months or ≥ 3 infections in 12 months) with or without symptoms of vaginal infection (regardless of having only uncomplicated UTI symptoms) 	18,788 (36.5)
Other ³	<ul style="list-style-type: none"> ● Patients reporting ≤ 1 of the 4 UTI symptoms, without symptoms of complicated infection, with or without symptoms of vaginal infection ● Patients reporting none of the 4 UTI symptoms with ≤ 1 of the complicated infection symptoms, with or without symptoms of vaginal infection ● Regardless of recurrent infection 	956 (1.9)

166 UTI, urinary tract infection.

167 ¹Uncomplicated UTI symptoms consisted of urinary frequency, urinary urgency, dysuria, and
 168 hematuria.

169 ²Complicated UTI symptoms consisted of an oral temperature greater than 99.5 °F; new onset of
 170 nausea and/or vomiting; new onset of feelings of general achiness/not feeling well; back,
 171 abdominal, side, or groin pain; international travel within the past 6 months; and dehydration
 172 within the past 2–3 weeks.

173 ³Symptoms of vaginal infections consisted of green, yellow, clear, or white discharge; odor from
 174 urine or discharge; and vaginal itching, blisters, lesions, or rash.

175

176 *Prescription use and antibiotic type.* Prescription use and antibiotic type were measured
177 by analyzing the number of appointments that resulted in prescriptions and the type and number
178 of medications that were prescribed. A standard clinical protocol was developed based on
179 guidelines for uncomplicated UTIs; thus, the recommended antibiotics were nitrofurantoin,
180 trimethoprim-sulfamethoxazole, and fosfomycin (see S1 Appendix) [18,22,26]. No standardized
181 protocol was developed for complicated UTIs and/or symptoms of vaginal infection. Physicians
182 were permitted to manage these cases according to their evaluation and discretion. However,
183 specific population-guided protocols were developed (e.g., for women older than 65 years,
184 patients with dual infections).

185 *Symptom resolution.* Patients received a survey 7 days after their appointment asking
186 them to indicate whether their symptoms had resolved.

187 *Treatment failure and relapse.* Appointments that occurred within 30 days after an initial
188 appointment were considered follow-up visits and reported as treatment failure or relapse. These
189 visits were excluded from the original analyses and were instead reported as outcomes of the
190 initial appointment. Due to insufficient data (e.g., it is unclear if most patients experienced any
191 symptom resolution between appointments), treatment failure and relapse were reported together
192 because these groups were indistinguishable.

193

194 *Statistical methods*

195 Descriptive statistics were used to summarize the study sample, including frequencies, means,
196 SDs, medians, and IQRs. Specifically, data were presented to examine prescription use and
197 symptom resolution by age and US census region, as well as by grouping those with

198 uncomplicated UTIs, complicated UTIs, and symptoms of vaginal infection. Number of
199 prescriptions received, type of prescription, symptom resolution, and number of treatment
200 failures/relapses by symptom profile category were also assessed. Symptom resolution rates were
201 compared, using chi-square tests, between the complicated and uncomplicated UTI symptom
202 groups and between all women who received a prescription medication with symptom resolution
203 among 8 comparator studies, for a total of 9 tests [14,29-35]. Bonferroni correction was used to
204 account for multiple tests, and p-values <0.005 were considered significant. All descriptive
205 statistics and chi-square tests were calculated in R (version 4.0.5) for Macintosh.

206

207 **Results**

208 The analysis set (n=51,474) included data from appointments with patients between the ages of
209 18 and 84 years (mean=39.4, SD=14.7). Most patients were between the ages of 22 to 46 years
210 (n=30,423, 59.1%), and the South census geographic region had the greatest number of patients
211 (n=20,172, 39.2%; see Table 2).

212

213 **Table 2. Patient characteristics.¹**

Characteristics	N (%) (N=51,474)
Age (years)	
18–21	3,791 (7.4)
22–45	30,423 (59.1)
46–65	14,449 (28.1)
≥66	2,811 (5.5)
Region (US Census Region) ²	
South	20,172 (39.2)
West	17,851 (34.7)
Midwest	9,970 (19.4)

Northeast	3,481 (6.8)
-----------	-------------

214 ¹Raw data counts by age and geographic region for each appointment. Individuals who used the
215 program multiple times appear more than once in this table.

216 ²Regions were determined via the US Census regions. West: Alaska, Arizona, California,
217 Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington,
218 Wyoming. Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New
219 York, Pennsylvania, Rhode Island, Vermont. Midwest: Illinois, Indiana, Iowa, Kansas,
220 Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, Wisconsin.
221 South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky,
222 Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas,
223 Virginia, West Virginia.

224

225 *Symptom presentation*

226 Overall, symptom prevalence was high for urinary frequency (n=48,574, 94.4%), urinary
227 urgency (n=48,662, 94.5%), and dysuria (n=50,244, 97.6%), while fewer patients reported
228 hematuria (n=8,381, 16.3%). The majority of appointments (n=31,730, 61.6%) consisted of
229 patients with uncomplicated UTI symptoms, but a substantial number (n=18,788, 36.5%)
230 reported complicated UTI symptoms (see Table 1). The remaining appointments (n=956, 1.9%)
231 consisted of patients in the other symptoms group. In total, 9,894 (19.2%) reported at least 1
232 symptom of vaginal infection: 5,142 (16.2%) in the uncomplicated UTI symptoms group, 4,618
233 (24.6%) in the complicated UTI symptoms group, and 134 (14.0%) in the other symptoms group.

234

235 *Prescription use and antibiotic choice*

236 Patients from 50,826 (98.7%) appointments received at least 1 prescription, with 2,818 (5.5%)
237 receiving more than 1 prescription. Patients from 44,304 (86.1%) appointments received 1
238 antibiotic, 2,320 (4.5%) received at least 1 antibiotic and an additional medication (e.g.,
239 phenazopyridine or fluconazole), 498 (1.0%) received 2 or more antibiotics without an additional

240 medication, and 5 (<0.01%) received 1 or more other medications without an antibiotic.

241 Prescription data were unavailable for 3,966 (7.7%) patient appointments on the platform.

242 Overall, clinical protocol adherence to recommended prescribing patterns was high
243 (n=43,932, 94.0%), and patients were most likely to receive prescriptions for antibiotics that
244 were recommended in the clinical protocol (see Table 3). This pattern was consistent across
245 patient groups: uncomplicated UTI symptoms (n=27,128, 94.4%), complicated UTI symptoms
246 (n=16,070, 93.7%), and other symptoms group (n=772, 88.0%). Most women who reported at
247 least 1 vaginal symptom, in addition to UTI symptoms, received a recommended antibiotic
248 (n=8,396, 84.9%).

249 **Table 3. Symptom groups and prescription counts.**

Symptom Group	Received a Prescription ¹ N (%)	Unknown Prescription ² N (%)	Received Antibiotic N (%) ³	Received “Recommended” Antibiotic N (%) ⁴	Nitrofurantoin N (%) ⁵	TMP-SMX N (%) ⁵	Fosfomycin N (%) ⁵	Ciprofloxacin (Regular or XR) N (%) ^{5, 6}
Total N=51,474 (100%)	50,826 (98.7)	3,699 (7.2)	46,754 (92.0)	43,932 (94.0)	24,581 (52.6)	19,404 (41.5)	23 (0.0)	2,431 (5.2)
UTI N=50,518 (98.1%)	49,903 (98.8)	3,657 (7.2)	45,877 (91.9)	43,160 (94.1)	24,200 (52.7)	19,010 (41.4)	23 (0.0)	2,346 (5.1)
Uncomplicated N=31,730 (62.8%)	31,431 (99.1)	2,471 (7.8)	28,727 (91.4)	27,128 (94.4)	15,235 (53.0)	11,913 (41.5)	15 (0.0)	1,402 (4.9)
Complicated N=18,788 (37.2%)	18,472 (98.3)	1,186 (6.3)	17,150 (94.8)	16,070 (93.7)	8,965 (52.3)	7,097 (41.4)	8 (0.0)	944 (5.5)
Other N=965 (1.9%)	923 (95.6)	42 (4.4)	877 (95.0)	772 (88.0)	381 (43.4)	394 (44.9)	0 (0.0)	85 (9.7)

250 TMP-SMX, trimethoprim-sulfamethoxazole; UTI, urinary tract infection; XR, extended-release.

251 ¹Patients who received >1 prescription are only included once in this column.

252 ²Some patients received a prescription, but there was no information about the prescription available in the dataset.

253 ³Percentage represents the number of patients who received ≥ 1 antibiotics out of the total number who received a prescription. Patients
254 who received >1 type of antibiotic are only included once.

255 ⁴A recommended antibiotic is defined by the clinical protocol, not by the patient’s self-reported symptoms, and include nitrofurantoin,
256 TMP-SMX, and fosfomycin. The percentage represents the number of patients who received a recommended antibiotic out of the total

257 number who received an antibiotic prescription. Note that 76 people received a prescription for nitrofurantoin and TMP-SMX; they
258 are only listed once in this column.

259 ⁵The percentages represent the number of patients who received that prescription out of the number of patients who received an
260 antibiotic.

261 ⁶Ciprofloxacin was an alternative regimen in the clinical protocol.


262

263

264 *Symptom resolution*

265 Symptom resolution data from the 7-day follow-up survey were available for 3,541 women,
 266 including 2,193 women in the uncomplicated UTI group, 1,241 women in the complicated UTI
 267 group, and 107 women in the other symptoms group. Across all groups, 99.4% of patients
 268 (n=3,521) received a prescription, and the majority of these patients reported 7-day symptom
 269 resolution (89.7%, n=3,160) compared with less than half of patients who did not receive a
 270 prescription (40.0%, n=8; see Table 4). The symptom resolution rate in the complicated UTI
 271 group was lower than that of the uncomplicated UTI group; however, this difference was not
 272 significant (see Fig 2). Among those with a UTI and at least one symptom of vaginal infection,
 273 the symptom resolution rates were similar for those with uncomplicated UTIs (86.2%) and
 274 complicated UTIs (85.5%). Across all groups, the symptom resolution rate among patients who
 275 received a prescription within this study was significantly higher than 4 of the 8 comparator
 276 studies ($\chi^2 = 20.0-374.1, p < 0.001$), significantly lower than 1 study ($\chi^2 = 11.9, p < 0.001$), and
 277 not significantly different from the remaining 3 studies (see Fig 2).

278



279 **Fig 2.** Forest plot of symptom resolution rates and 99% confidence intervals among all
 280 consultations, by UTI symptom group, and 8 previous studies' reported rates. **"UTI
 281 Telemedicine Platform All" refers to all consultations with associated 7-day follow-up symptom
 282

283 resolution data from the current study, followed by each symptom category. Among the
 284 comparator studies, symptom resolution was measured on different days, including the
 285 following: 3 days [35], 4 days [14], 4 to 7 days [31], 5 to 9 days [32,34], 7 days [30], 8 to 10
 286 days [33], and 9 to 15 days [29]. Of the 8 comparator studies, 7 used in-person standard-of-care
 287 [14,29-34] and 1 used telemedicine services [35]. If the comparator study was a clinical trial with
 288 a control group, then symptom resolution rates were only compared with treatment groups who
 289 received antibiotics [14].
 290

291 **Table 4. Symptom resolution stratified by symptom group and receiving a prescription or**
 292 **not.¹**

Symptoms	N (%)												
	Uncomplicated UTI Symptoms (n=2,193)		Complicated UTI Symptoms (n=1,241)		Other Symptoms (n=107)		Uncomplicated UTI & Vaginal Symptom (n=276)		Complicated UTI & Vaginal Symptom (n=262)		Total		Total
	Rx	No Rx	Rx	No Rx	Rx	No Rx	Rx	No Rx	Rx	No Rx	Rx	No Rx	
Resolved	1,984 (90.8)	4 (50.0)	1081 (87.9)	4 (36.4)	95 (89.6)	0 (0.0)	238 (86.5)	0 (0.0)	223 (86.4)	1 (25.0)	3,160 (89.7)	8 (40.0)	3,168 (89.5)
Unresolved	201 (9.2)	4 (50.0)	149 (12.1)	7 (63.6)	11 (10.4)	1 (100.0)	37 (13.5)	1 (100.0)	35 (13.6)	3 (75.0)	361 (10.3)	12 (60.0)	373 (10.5)
Total	2,185	8	1,230	11	106	1	275	1	258	4	3,521	20	3,541

293 Rx, prescription; UTI, urinary tract infection.

294 ¹“Rx” includes individuals who were prescribed any prescription medication.

295

296 *Treatment failure and relapse*

297 Overall, 1,156 (2.2%) patients returned to use the program within 30 days after their original

298 consultation: 264 patients (22.8%) returned within 7 days, 328 patients (28.4%) within 8 to 14

299 days, and 564 patients (48.8%) between 15 and 30 days after the initial appointment.

300

301 **Discussion**

302 To the authors' knowledge, this is the largest analysis of real-world data from a telemedicine
303 service for treating UTIs to date. Data from 51,474 visits over 4 years indicated that patients
304 from 98.1% of appointments self-reported at least 2 symptoms of uncomplicated or complicated
305 UTIs, with dysuria being the most commonly reported symptom. More than half (52.4%) of the
306 sample reported at least 1 symptom of complicated UTI or vaginal infection. Most appointments
307 (98.7%) resulted in a prescription, and prescription use and type were similar regardless of
308 patient-reported symptoms (uncomplicated UTI, complicated UTI, or vaginal infection). Most
309 patients (94.0%) with available prescription data received antibiotics that were recommended in
310 the protocol (nitrofurantoin, trimethoprim-sulfamethoxazole, and fosfomycin).

311 Of patients with available follow-up survey data, 89.5% reported symptom resolution,
312 and resolution rates were similar between uncomplicated and complicated UTI groups.
313 Furthermore, the symptom resolution rate across all UTI categories was similar to previous
314 research on UTI telemedicine programs evaluating only uncomplicated UTI patients. Only 2.2%
315 of patients returned to the program within 30 days after an initial appointment, suggesting low
316 treatment failure and relapse rates. Resolution rates among uncomplicated and complicated UTIs
317 were also similar to, or better than, previous reports of in-person standard of care (see Fig 2).
318 Taken together, this analysis demonstrates the effectiveness of large-scale UTI telemedicine
319 programs and extends those observations to include patients who self-report symptoms of
320 complicated UTIs or vaginal infections. Although this study made no direct measurements
321 regarding safety, a retrospective study evaluating the safety and efficacy of telemedicine
322 management of uncomplicated UTIs in 526 women reported that teleprescription of antibiotics is
323 as safe as prescriptions initiated during in-person consultations [35]. Overall, 78% of patients

324 reported complete symptom resolution 3 days following teleconsultation, while 14% reported a
325 decrease in uncomplicated UTI symptoms. Four percent reported deterioration, such as increased
326 pain, flank pain, or fever, and 5% reported antibiotic adverse effects [35].

327 Previous research has reported that women perform well at self-diagnosing UTIs [36].
328 Despite self-reporting symptoms of complicated UTIs or vaginal infections, these data support
329 the notion that the women using this telemedicine program were accurately able to self-identify
330 that they had a UTI. Furthermore, through discussions with physicians, these patients may have
331 clarified the presence and severity of complicated UTIs or vaginal symptoms, which may have
332 emboldened physicians to provide care for women who self-reported these symptoms at intake.
333 Women who self-reported complicated UTI and vaginal symptoms had similar resolution rates
334 compared with those who reported uncomplicated UTIs symptoms. Thus, these data suggest that
335 a telemedicine approach to identification and treatment of more complicated UTIs and vaginal
336 symptoms may be effective. Further work to determine appropriate sub-grouping and
337 standardized protocols for these conditions is likely warranted. Of note, if the program had
338 excluded patients who reported complicated UTI or symptoms of vaginal infection, 24,064
339 women (approximately half of the sample) would have required in-person care, either through
340 primary care, urgent care, or emergency department visits.

341 At scale, telemedicine programs that include uncomplicated and complicated UTIs could
342 be a complementary offering at primary care clinics. This complementary service may result in
343 reduced provider burdens within those settings, as well as within urgent care or emergency
344 departments, freeing up valuable resources, without compromising quality of care or resolution
345 rates. Undeniably, telemedicine access for UTI assessment and treatment can lessen the patient
346 burden of in-person care. Future studies may identify the most effective protocols for integrating

347 such services into the existing primary care setting, or even into urgent care centers and
348 emergency departments.

349 Another noteworthy outcome of this analysis was that telemedicine physician adherence
350 to recommended antibiotic protocols was higher than previously reported, according to
351 concordance with the Infectious Diseases Society of America guidelines for antibiotics to treat
352 UTIs [37,38]. The telemedicine physicians in this sample were adherent to these guidelines for
353 94.0% of appointments that resulted in antibiotic prescriptions. This high adherence rate may
354 have been due to the implementation of the protocol and ease of use [39]. Moreover, provider
355 prescribing practices were regularly audited to assure compliance. The recommended antibiotics
356 in the clinical protocol were based on the guidelines for patients with uncomplicated UTIs
357 [26,40]. Although not detailed in the current clinical protocol, the recommended antibiotic
358 regimens may differ for patients exhibiting symptoms of pyelonephritis or complicated infection
359 [40]. Telemedicine programs that allow for patients with symptoms of complicated UTIs or
360 vaginal infections to receive appointments should include specific instructions for assessing the
361 severity of the infection, the potential need for STI testing, and other medications that should be
362 considered if a UTI diagnosis is not suspected.

363

364 *Limitations*

365 As with all real-world evidence, the data used in this analysis were limited by what was collected
366 through the clinical program. The present analysis relied on inferred diagnosis determined from
367 digital responses and patient-reported symptoms at intake. Diagnoses made during treatment
368 consultations were not obtained. As telemedicine programs become more ubiquitous,
369 incorporating post-encounter diagnosis codes would provide greater granularity and

370 understanding of treatment patterns and outcomes, particularly for those with more complicated
371 cases or other symptoms that may be addressed as part of the telemedicine encounter. Integrating
372 these types of programs into electronic health records diagnosis information would allow
373 researchers to identify patients who inaccurately report their symptoms. Future work is needed to
374 determine discrepancies between patient-reported symptoms on intake and physicians' diagnoses
375 based on direct patient encounters. This knowledge would help to expand clinical protocols to
376 include guidance for determining the risk levels and appropriate next steps for patients who
377 report symptoms of complicated UTI or vaginal infection.

378 The current analysis evaluated symptom resolution data for a total of 3,541 appointments,
379 representing only 6.9% of the population. Although this still represents a large cohort in both the
380 uncomplicated and complicated UTI groups, we can only speculate a similar rate of symptom
381 resolution over the entire sample population. Notably, patients who did not experience symptom
382 resolution were offered additional care, including referral to in-person care, and as such no
383 symptom resolution data may have been available. A small percentage of patients (2.2%)
384 returned to use the program within 30 days after the initial consultation, suggesting that most
385 patients experienced a full recovery or sought in-person/other care, a feature this analysis cannot
386 resolve. Patient follow-up data are needed to better understand symptom resolution when using
387 direct-to-consumer telemedicine services. Future research may provide insight into how to
388 ensure patients self-report symptom resolution, or perhaps, how data from electronic health
389 records may be used to assess follow-up engagement with in-person care services.

390

391 **Conclusion**

392 Telemedicine services make it easier and faster for patients to receive treatment for UTIs by
393 eliminating travel and waiting time at emergency rooms. This analysis demonstrates that
394 telemedicine programs are an effective and scalable option for treatment of UTIs, even for
395 women who self-report symptoms of complicated UTIs or vaginal infection. Most patients in the
396 program exhibited symptoms of uncomplicated or complicated UTIs. Of those patients with
397 available follow-up data, most experienced symptom resolution within 7 days after their
398 appointment. Implementing and scaling UTI telemedicine programs and including women who
399 self-report symptoms of complicated UTI or vaginal infection can reduce the burden on urgent
400 care facilities and emergency departments, without compromising on the quality of care.

401

402

403 **Acknowledgments**

404 The authors would like to acknowledge the following people who developed and managed the
405 telemedicine program evaluated in this study: Yvette Gaudreau, Lara Goorland, Anthony
406 Dearman, Gabe Gaviola, Adina Schwartz, Jennifer Jing, Emily Miller, and Doug Elwood.
407 Additionally, writing support was provided by Virgo Health.

408

409

410 **Competing Interests**

411 Natalie Daumeyer, Daniel Kreitzberg, Kathleen Gavin, and Timothy Bauer were all employees
412 of Everly Health, Inc. at the time this analysis was conducted.

413

414

References

- 415 1. Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2007.
416 Vital Health Stat 13. 2011;(169):1-38.
- 417 2. Chou SC, Baker O, Schuur JD. Changes in emergency department care intensity from
418 2007-16: analysis of the National Hospital Ambulatory Medical Care survey. West J Emerg
419 Med. 2020;21(2):209-216. doi:10.5811/westjem.2019.10.43497.
- 420 3. Stein JC, Navab B, Frazee B, Tebb K, Hendey G, Maselli J, et al. A randomized trial of
421 computer kiosk-expedited management of cystitis in the emergency department. Acad Emerg
422 Med. 2011;18(10):1053-1059. doi:10.1111/j.1553-2712.2011.01167.x.
- 423 4. Bashshur RL, Reardon TG, Shannon GW. Telemedicine: a new health care delivery
424 system. Annu Rev Public Health. 2000;21:613-637. doi:10.1146/annurev.publhealth.21.1.613.
- 425 5. Bono MJ, Leslie SW, Reygaert WC. Urinary tract infection. In: StatPearls [Internet].
426 Treasure Island (FL): StatPearls Publishing; 2022.
- 427 6. Taur Y, Smith MA. Adherence to the Infectious Diseases Society of America guidelines
428 in the treatment of uncomplicated urinary tract infection. Clin Infect Dis. 2007;44(6):769-774.
429 doi:10.1086/511866.
- 430 7. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk
431 factors, and disease burden. Infect Dis Clin North Am. 2014;28(1):1-13.
432 doi:10.1016/j.idc.2013.09.003.
- 433 8. Ozturk T, Talo M, Yildirim EA, Baloglu UB, Yildirim O, Acharya UR. Automated
434 detection of COVID-19 cases using deep neural networks with X-ray images. Comput Biol Med.
435 2020;121:103792. doi:10.1016/j.combiomed.2020.103792.

- 436 9. Campbell J, Felver M, Kamarei S. ‘Telephone treatment’ of uncomplicated acute cystitis.
437 Cleve Clin J Med. 1999;66(8):495-501. doi:10.3949/ccjm.66.8.495.
- 438 10. Saint S, Scholes D, Fihn SD, Farrell RG, Stamm WE. The effectiveness of a clinical
439 practice guideline for the management of presumed uncomplicated urinary tract infection in
440 women. Am J Med. 1999;106(6):636-641. doi:10.1016/s0002-9343(99)00122-9.
- 441 11. Barry HC, Hickner J, Ebell MH, Ettenhofer T. A randomized controlled trial of telephone
442 management of suspected urinary tract infections in women. J Fam Pract. 2001;50(7):589-594.
- 443 12. Vinson DR, Quesenberry CP, Jr. The safety of telephone management of presumed
444 cystitis in women. Arch Intern Med. 2004;164(9):1026-1029. doi:10.1001/archinte.164.9.1026.
- 445 13. Schauburger CW, Merkitich KW, Prell AM. Acute cystitis in women: experience with a
446 telephone-based algorithm. WMJ. 2007;106(6):326-329.
- 447 14. Bollestad M, Grude N, Lindbaek M. A randomized controlled trial of a diagnostic
448 algorithm for symptoms of uncomplicated cystitis at an out-of-hours service. Scand J Prim
449 Health Care. 2015;33(2):57-64. doi:10.3109/02813432.2015.1041827.
- 450 15. Rastogi R, Martinez KA, Gupta N, Rood M, Rothberg MB. Management of urinary tract
451 infections in direct to consumer telemedicine. J Gen Intern Med. 2020;35(3):643-648.
452 doi:10.1007/s11606-019-05415-7.
- 453 16. Bent S, Nallamotheu BK, Simel DL, Fihn SD, Saint S. Does this woman have an acute
454 uncomplicated urinary tract infection? JAMA. 2002;287(20):2701-2710.
455 doi:10.1001/jama.287.20.2701.
- 456 17. Little P, Moore MV, Turner S, Rumsby K, Warner G, Lowes JA, et al. Effectiveness of
457 five different approaches in management of urinary tract infection: randomised controlled trial.
458 BMJ. 2010;340:c199. doi:10.1136/bmj.c199.

- 459 18. Gupta K, Grigoryan L, Trautner B. Urinary tract infection. *Ann Intern Med*.
460 2017;167(7):ITC49-ITC64. doi:10.7326/aitc201710030.
- 461 19. Sabih A, Leslie SW. Complicated urinary tract infections. 2022 May 27. In: StatPearls
462 [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
- 463 20. Smith WB, II, Kohlwes RJ. From leather bags to webcams, the emerging tools of tele-
464 primary care. *J Gen Intern Med*. 2020;35(3):628-629. doi:10.1007/s11606-019-05603-5.
- 465 21. Giesen LGM, Cousins G, Dimitrov BD, van de Laar FA, Fahey T. Predicting acute
466 uncomplicated urinary tract infection in women: a systematic review of the diagnostic accuracy
467 of symptoms and signs. *BMC Fam Pract*. 2010;11:78. doi:10.1186/1471-2296-11-78.
- 468 22. Colgan R, Williams M. Diagnosis and treatment of acute uncomplicated cystitis. *Am*
469 *Fam Physician*. 2011;84(7):771-776.
- 470 23. Garland SM, Tabrizi SN. Diagnosis of sexually transmitted infections (STI) using self-
471 collected non-invasive specimens. *Sex Health*. 2004;1(2):121-126. doi:10.1071/sh03014.
- 472 24. Alidjanov JF, Naber KG, Abdufattaev UA, Pilatz A, Wagenlehner FM. Reliability of
473 symptom-based diagnosis of uncomplicated cystitis. *Urol Int*. 2019;102(1):83-95.
474 doi:10.1159/000493509.
- 475 25. Goebel MC, Trautner BW, Grigoryan L. The five Ds of outpatient antibiotic stewardship
476 for urinary tract infections. *Clin Microbiol Rev*. 2021;34(4):e0000320. doi:10.1128/cmr.00003-
477 20.
- 478 26. Grigoryan L, Trautner BW, Gupta K. Diagnosis and management of urinary tract
479 infections in the outpatient setting: a review. *JAMA*. 2014;312(16):1677-1684.
480 doi:10.1001/jama.2014.12842.

- 481 27. U.S. Department of Health and Human Services. Complicated urinary tract infections:
482 developing drugs for treatment. Guidance for industry. 2018. Available at
483 [https://www.fda.gov/regulatory-information/search-fda-guidance-documents/complicated-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/complicated-urinary-tract-infections-developing-drugs-treatment)
484 [urinary-tract-infections-developing-drugs-treatment](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/complicated-urinary-tract-infections-developing-drugs-treatment). Accessed on April 20, 2022.
- 485 28. Belyayeva M, Jeong JM. Acute pyelonephritis. 2022 Jul 5. In: StatPearls [Internet].
486 Treasure Island (FL): StatPearls Publishing; 2022.
- 487 29. Spencer RC, Moseley DJ, Greensmith MJ. Nitrofurantoin modified release versus
488 trimethoprim or co-trimoxazole in the treatment of uncomplicated urinary tract infection in
489 general practice. *J Antimicrob Chemother.* 1994;33 Suppl A:121-129.
490 doi:10.1093/jac/33.suppl_a.121.
- 491 30. Stein GE. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in
492 female patients with uncomplicated urinary tract infection. *Clin Ther.* 1999;21(11):1864-1872.
493 doi:10.1016/s0149-2918(00)86734-x.
- 494 31. Kavatha D, Giamarellou H, Alexiou Z, Vlachogiannis N, Pentea S, Gozadinos T, et al.
495 Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of
496 uncomplicated acute cystitis in women. *Antimicrob Agents Chemother.* 2003;47(3):897-900.
497 doi:10.1128/aac.47.3.897-900.2003.
- 498 32. Arredondo-García JL, Figueroa-Damián R, Rosas A, Jáuregui A, Corral M, Costa A, et
499 al. Comparison of short-term treatment regimen of ciprofloxacin versus long-term treatment
500 regimens of trimethoprim/sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract
501 infections: a randomized, multicentre, open-label, prospective study. *J Antimicrob Chemother.*
502 2004;54(4):840-843. doi:10.1093/jac/dkh414.

- 503 33. Ferry SA, Holm SE, Stenlund H, Lundholm R, Monsen TJ. Clinical and bacteriological
504 outcome of different doses and duration of pivmecillinam compared with placebo therapy of
505 uncomplicated lower urinary tract infection in women: the LUTIW project. *Scand J Prim Health*
506 *Care*. 2007;25(1):49-57. doi:10.1080/02813430601183074.
- 507 34. Gupta K, Hooton TM, Roberts PL, Stamm WE. Short-course nitrofurantoin for the
508 treatment of acute uncomplicated cystitis in women. *Arch Intern Med*. 2007;167(20):2207-2212.
509 doi:10.1001/archinte.167.20.2207.
- 510 35. Blozik E, Sommer-Meyer C, Cerezo M, von Overbeck J. Effectiveness and safety of
511 telemedical management in uncomplicated urinary tract infections. 2011;17(2):78-82.
512 doi:10.1258/jtt.2010.100406.
- 513 36. Gupta K, Hooton TM, Roberts PL, Stamm WE. Patient-initiated treatment of
514 uncomplicated recurrent urinary tract infections in young women. *Ann Intern Med*.
515 2001;135(1):9-16. doi:10.7326/0003-4819-135-1-200107030-00004.
- 516 37. Zatorski C, Zocchi M, Cosgrove SE, Rand C, Brooks G, May L. A single center
517 observational study on emergency department clinician non-adherence to clinical practice
518 guidelines for treatment of uncomplicated urinary tract infections. *BMC Infect Dis*.
519 2016;16(1):638. doi:10.1186/s12879-016-1972-6.
- 520 38. Grigoryan L, Zoorob R, Wang H, Trautner BW. Low concordance with guidelines for
521 treatment of acute cystitis in primary care. *Open Forum Infect Dis*. 2015;2(4):ofv159.
522 doi:10.1093/ofid/ofv159.
- 523 39. Grigoryan L, Nash S, Zoorob R, Germanos GJ, Horsfield MS, Khan FM, et al.
524 Qualitative analysis of primary care provider prescribing decisions for urinary tract infections.
525 *Antibiotics (Basel)*. 2019;8(2). doi:10.3390/antibiotics8020084.

526 40. Gupta K, Hooton TM, Naber KG, Wult B, Colgan R, Miller LG, et al. International
527 clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in
528 women: a 2010 update by the Infectious Diseases Society of America and the European Society
529 for Microbiology and Infectious Diseases. *Clin Infect Dis.* 2011;52(5):e103-e120.
530 doi:10.1093/cid/ciq257.

531 **S1 Appendix: Prescription Information**

Recommended Regimens		
Nitrofurantoin 100 mg, twice per day for 5 days	Trimethoprim-sulfamethoxazole 160–800 mg twice per day for 3 days	Fosfomycin 3 g single dose
Alternative Regimens		
Ciprofloxacin* 250 mg twice per day for 3 days	Ciprofloxacin extended release* 500 mg once per day for 3 days	Levofloxacin* 250 mg once per day for 3 days
Ofloxacin* 400 mg single dose	Amoxicillin-clavulanate† 500–125 mg twice per day for 3–7 days	Cefpodoxime† 100 mg twice per day for 3–7 days
Cefdinir† 300 mg twice per day for 3–7 days	Cefaclor† 250 mg or 500 mg 3 times per day for 3–7 days	Cefadroxil† 500 mg twice per day for 3–7 days

532 *Fluoroquinolones

533 †Beta lactams